Cullinan Therapeutics (CGEM) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Vor Biopharma (VOR) over the past year, gaining 165.4% versus a loss of 44.4%. Over five years, CGEM leads with a -37.5% price change compared with -93.9% for VOR. Vor Biopharma is the larger company by market cap ($1.11 billion vs $960.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | VOR |
|---|---|---|
| Share price | $15.63 | $18.78 |
| Market cap | $960.59M | $1.11B |
| 1-day change | -3.82% | +2.57% |
| YTD return | +51.01% | +43.58% |
| 1-year return | +165.37% | -44.44% |
| 5-year return | -37.48% | -93.93% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-3.11 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $34.63 |
| 52-week low | $5.85 | $6.50 |
| Distance from 52-week high | -32.60% | -45.77% |
| Average volume | 868.12K | 1.02M |
| Shares outstanding | 61.46M | 59.16M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed VOR by 209.8 percentage points over the past year.
CGEM vs VOR FAQ
Which is bigger, Cullinan Therapeutics or Vor Biopharma?
Vor Biopharma (VOR) is larger, with a market capitalization of $1.11B compared with $960.59M for Cullinan Therapeutics (CGEM).
Which stock has performed better over the past year, CGEM or VOR?
CGEM returned +165.37% over the past 12 months, compared with -44.44% for VOR (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.